Volume 11, Number 10—October 2005
Research
Methicillin-resistant Staphylococcus aureus and Vancomycin-resistant Enterococci Co-colonization1
Jon P. Furuno*
, Eli N. Perencevich*†‡, Judith A. Johnson*†, Marc-Oliver Wright‡2, Jessina C. McGregor*, J. Glenn Morris*†, Sandra M. Strauss*, Mary-Claire Roghman*†, Lucia L. Nemoy*†, Harold C. Standiford‡, Joan N. Hebden‡, and Anthony D. Harris*†‡
, Eli N. Perencevich*†‡, Judith A. Johnson*†, Marc-Oliver Wright‡2, Jessina C. McGregor*, J. Glenn Morris*†, Sandra M. Strauss*, Mary-Claire Roghman*†, Lucia L. Nemoy*†, Harold C. Standiford‡, Joan N. Hebden‡, and Anthony D. Harris*†‡
Table 1
Characteristics of the study population by co-colonization status*
| Characteristic | MRSA/VRE co-colonization (n = 65) | No co-colonization (n = 2,375) | p value |
|---|---|---|---|
| Demographic variable | |||
| Mean age, y (SD) | 61.1 (15.1) | 55.7 (16.0) | <0.01 |
| Male sex, n (%) | 43 (66.2) | 1,277 (53.8) | 0.05 |
| Variables from current admission | |||
| Type of ICU (MICU), n (%) | 49 (75.4) | 1,014 (42.7) | <0.01 |
| Transfer from another hospital, n (%) | 10 (15.4) | 711 (29.9) | <0.01 |
| Comorbidities | |||
| HIV/AIDS, n (%) | 3 (4.6) | 77 (3.2) | 0.54 |
| Malignancy, n (%) | 6 (9.2) | 423 (17.8) | 0.07 |
| Cardiac disease, n (%) | 20 (30.8) | 486 (20.5) | 0.04 |
| Diabetes mellitus, n (%) | 14 (21.5) | 486 (20.5) | 0.83 |
| Liver disease, n (%) | 2 (3.1) | 182 (7.7) | 0.17 |
| Renal disease, n (%) | 3 (4.6) | 74 (3.1) | 0.50 |
| Mean Charlson comorbidity score (SD) | 2.1 (2.2) | 2.3 (2.3) | 0.37 |
| Antimicrobial drugs before culture | |||
| Vancomycin, n (%) | 14 (21.5) | 226 (9.5) | <0.01 |
| Piperacillin-tazobactam, n (%) | 17 (26.2) | 398 (16.8) | 0.05 |
| Imipenem, n (%) | 2 (3.1) | 72 (3.0) | 0.98 |
| Cephalosporins, n (%) | 7 (10.8) | 426 (17.9) | 0.14 |
| Aminoglycosides, n (%) | 4 (6.2) | 109 (4.6) | 0.55 |
| Fluoroquinolones, n (%) | 11 (16.9) | 223 (9.4) | 0.04 |
| Variables from previous admissions | |||
| Previous MRSA colonization/infection | 31 (47.7) | 145 (6.1) | <0.01 |
| Previous VRE colonization/infection | 18 (27.7) | 178 (7.5) | <0.01 |
| Hospital admission (<1 y), n (%) | 37 (57.9) | 751 (31.6) | <0.01 |
| ICU admission (<1 y), n (%) | 17 (26.2) | 309 (13.0) | <0.01 |
| Antimicrobial drugs during admission (<1 y), n (%) | 33 (50.8) | 606 (25.5) | <0.01 |
*MRSA, methicillin-resistant Staphylococcus aureus; VRE, vancomycin-resistant enterococci; SD, standard deviation; ICU, intensive care unit; MICU, medical ICU.
1These data were presented in part at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, September 2004.
2Current affiliation: Marshfield Clinic Research Foundation, Marshfield, Wisconsin, USA.
Page created: February 22, 2012
Page updated: February 22, 2012
Page reviewed: February 22, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.